Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 14/20 | 0.96 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8232157 | 0.98 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7427277 | 0.98 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5142091 | 0.93 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28171895 | 0.91 | EPHX1 (0.95) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13459981 | 0.90 | EPHX1 (0.78) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19086886 | 0.88 | EPHX1 (0.91) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11877122 | 0.85 | EPHX1 (0.94) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23960132 | 0.83 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24308699 | 0.83 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24308701 | 0.83 | EPHX1 (1.00) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104395302-A | 1- [ m-carboxamido (hetero) aryl-methyl ] -heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD | 2015-03-04 | — | — | CN | disclosed |
| WO-2014082889-A1 | NOVEL IMIDAZOLINES AS DUAL INHIBITORS OF MDM2 AND MDMX | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | HOFFMANN-LA ROCHE INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | MDM2, MDM4, TP53 | EPHX1 2554/4885EPHX2 2907/4885NPC1 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.